.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,143,327

« Back to Dashboard

Claims for Patent: 6,143,327

Title: Delayed release coated tablet of bupropion hydrochloride
Abstract:The invention provides a delayed release coated tablet, free of stabilizer and free of pore-forming agent comprising: (i) a core consisting essentially of bupropion hydrochloride, a binder and a lubricant; and (ii) a first coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer; and (iii) a second coating consisting essentially of a methacrylic polymer and a plasticizer therefor.
Inventor(s): Seth; Pawan (Irvine, CA)
Assignee: Pharma Pass LLC (Irvine, CA)
Application Number:09/459,459
Patent Claims: 1. A delayed release coated tablet comprising:

(i) a core comprising bupropion hydrochloride and conventional excipients, free of stabilizer; and

(ii) a first coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer; and

(iii) a second coating consisting essentially of a methacrylic polymer and a plasticizer therefor;

exhibiting a dissolution profile such that after 2 hours, from 0 up to 30% of the bupropion hydrochloride is released, after 4 hours, from 3 to 22% of the bupropion hydrochloride is released, after 6 hours, from 15 to 38% of the bupropion hydrochloride is released, after 8 hours, more than 40% of the bupropion hydrochloride is released.

2. The tablet of claim 1, where the water-insoluble, water-permeable film-forming polymer is ethylcellulose.

3. The tablet of claim 1, where the water-soluble polymer is polyvinylpyrrolidone.

4. The tablet of claim 1, where the plasticizer is 25 polyethyleneglycol.

5. The tablet of claim 1, where the methacrylic polymer is a methacrylic acid co-polymer.

6. The tablet of claim 1, where the plasticizer for the methacrylic polymer is triethyl citrate, polyethyleneglycol or a mixture thereof.

7. The tablet of claim 1, where in the first coating, the 35 water-insoluble, water-permeable film-forming polymer is ethylcellulose, the water-soluble polymer is polyvinylpyrrolidone, the plasticizer is polyethyleneglycol and where in the second coating, the methacrylic polymer is a methacrylic acid co-polymer, the plasticizer is triethyl citrate, polyethyleneglycol or a mixture thereof.

8. The tablet of claim 1, where the core comprises a binder and a lubricant.

9. The tablet of claim 8, where the core comprises polyvinyl alcohol and glyceryl behenate.

10. The tablet of claim 1, comprising from 50 to 400 mg bupropion hydrochloride.

11. The tablet of claim 7, comprising from 50 to 400 mg bupropion hydrochloride.

12. The tablet of claim 9, comprising from 50 to 400 mg bupropion hydrochloride.

13. A delayed release coated tablet comprising:

(i) a core consisting essentially of bupropion hydrochloride, polyvinylalcohol and glyceryl behenate; and

(ii) a first coating consisting essentially of ethylcellulose, polyvinylpyrrolidone and polyethyleneglycol; and

(iii) a second coating consisting essentially of methacrylic acid co-polymer, triethyl citrate, polyethyleneglycol and optionally silicon dioxide;

exhibiting a dissolution profile such that after 2 hours, from 0 up to 30% of the bupropion hydrochloride is released, after 4 hours, from 3 to 22% of the bupropion hydrochloride is released, after 6 hours, from 15 to 38% of the bupropion hydrochloride is released, after 8 hours, more than 40% of the bupropion hydrochloride is released.

14. The tablet of claim 13, comprising from 50 to 400 mg bupropion hydrochloride.

15. A bupropion hydrochloride delayed release coated tablet free of stabilizer and free of pore-forming agent, exhibiting a dissolution profile such that after 2 hours, from 0 up to 30% of the bupropion hydrochloride is released, after 4 hours, from 3 to 22% of the bupropion hydrochloride is released, after 6 hours, from 15 to 38% of the bupropion hydrochloride is released, after 8 hours, more than 40% of the bupropion hydrochloride is released.

16. The tablet of claim 15, comprising from 50 to 400 mg bupropion hydrochloride.

17. A tablet comprising the delayed release coated tablet of claim 1, coated with a bupropion hydrochloride immediate release coating.

18. A tablet comprising the delayed release coated tablet of claim 13, coated with a bupropion hydrochloride immediate release coating.

19. A tablet comprising the delayed release coated tablet of claim 15, coated with a bupropion hydrochloride immediate release coating.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc